M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

November 9, 2020

Study Completion Date

September 30, 2022

Conditions
Biliary Tract CancerCholangiocarcinomaGallbladder Cancer
Interventions
DRUG

M7824

Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.

Trial Locations (33)

333

Chang Gung Memorial Hospital, Linkou, Linkou District

704

National Cheng Kung University Hospital, Tainan City

8035

Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona

13620

Seoul National University Bundang Hospital, Seongnam-si

20089

Istituto Clinico Humanitas, Rozzano

20133

Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan

21231

Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore

28050

Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia, Madrid

32224

Mayo Clinic in Florida - Department of Neurology, Jacksonville

33604

Groupe Hospitalier Sud - Hôpital Haut Lévêque - Service Hepato Gastroentérologie Oncologie Digest, Pessac

40138

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi - Unita' Operativa di Pediatria, Bologna

44805

ICO - Site René Gauducheau, Saint-Herblain

55905

Mayo Clinic - Rochester, Rochester

77030

MD Anderson Cancer Center - Unit, Houston

85259

Mayo Clinic Arizona, Scottsdale

94158

UCSF Mount Zion Medical Ctr, San Francisco

94805

Institut Gustave Roussy, Villejuif

100142

Peking University Cancer Hospital, Beijing

150081

Affiliated Tumor Hospital of Harbin Medical University, Harbin

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa

00168

Policlinico Universitario Agostino Gemelli - UOC Oncologia Medica, Roma

104-0045

National Cancer Center Hospital - Dept of Hepatobiliary and Pancreatic Oncology, Chūōku

277-8577

National Cancer Center Hospital East, Kashiwa-shi

181-8611

Kyorin University Hospital - Dept of Oncology, Mitaka-shi

589-8511

Kindai University Hospital - Dept of Gastroenterology, Osakasayama-shi

241-8515

Kanagawa Cancer Center, Yokohama

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

05505

Asan Medical Center, Seoul

135-710

Samsung Medical Center, Seoul

08027

Hospital de la Santa Creu i Sant Pau, Barcelona

Unknown

National Taiwan University Hospital, Taipei

LS9 7TF

St James's University Hospital - Dept of Oncology, Leeds

All Listed Sponsors
collaborator

Merck KGaA, Darmstadt, Germany

INDUSTRY

lead

EMD Serono Research & Development Institute, Inc.

INDUSTRY

NCT03833661 - M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer) | Biotech Hunter | Biotech Hunter